Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Adrenergic beta-2 Receptor Agonists / administration & dosage Bronchodilator Agents / administration & dosage Delayed-Action Preparations Drug Combinations Forced Expiratory Volume Humans Muscarinic Antagonists / administration & dosage Network Meta-Analysis Pulmonary Disease, Chronic Obstructive / drug therapy Randomized Controlled Trials as Topic

Journal

Pulmonary pharmacology & therapeutics
ISSN: 1522-9629
Titre abrégé: Pulm Pharmacol Ther
Pays: England
ID NLM: 9715279

Informations de publication

Date de publication:
12 2019
Historique:
received: 02 07 2019
revised: 21 07 2019
accepted: 10 09 2019
pubmed: 15 9 2019
medline: 4 9 2020
entrez: 15 9 2019
Statut: ppublish

Résumé

Despite several long-acting β

Identifiants

DOI: 10.1016/j.pupt.2019.101841 PMID: 31520718
pubmed: 31520718
pii: S1094-5539(19)30163-4
doi: 10.1016/j.pupt.2019.101841
pii:
doi:

Substances chimiques

Adrenergic beta-2 Receptor Agonists 0
Bronchodilator Agents 0
Delayed-Action Preparations 0
Drug Combinations 0
Muscarinic Antagonists 0

Types de publication

Comparative Study Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101841

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Paola Rogliani (P)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Electronic address: paola.rogliani@uniroma2.it.

Maria Gabriella Matera (MG)

Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Beatrice Ludovica Ritondo (BL)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Ilaria De Guido (I)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Ermanno Puxeddu (E)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Mario Cazzola (M)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Luigino Calzetta (L)

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents adrénergiques › Agonistes adrénergiques › Agonistes bêta-adrénergiques › Agonistes des récepteurs béta-2 adrénergiques › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents de l'appareil respiratoire › Antiasthmatiques › Bronchodilatateurs › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Préparations à action retardée › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Ventilation pulmonaire › Volume expiratoire maximal par seconde › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents cholinergiques › Antagonistes cholinergiques › Antagonistes muscariniques › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méta-analyse comme sujet › Méta-analyse en réseau › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Efficacy and cardiovascular safety profile of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Efficacy and cardiovascular safety profile of...